Clinical Trials Sponsored by Jiangsu Cancer Institute & Hospital

Total 3958 results

Jiangsu Cancer Institute & Hospital

Not yet recruiting

Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Stage IVa Nasopharyngeal Carcinoma

Stage IVA Nasopharyngeal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC

Non-squamous NSCLC

China
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Recruiting

A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) (CHIC)

Lung Cancer, Non-small Cell

China
Jiangsu Cancer Institute & Hospital

Unknown

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

Diffuse Large B-Cell Lymphoma (DLBCL)

China
Jiangsu Cancer Institute & Hospital

Recruiting

A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.

GBM

China
Jiangsu Cancer Institute & Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM (HaRyPOT)

Colorectal Liver Metastases

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
Jiangsu Cancer Institute & Hospital

Recruiting

Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (LATE)

Chemoradiation | Esophageal Squamous Cell Carcinoma | Tislelizumab

China
Jiangsu Cancer Institute & Hospital

Recruiting

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Jiangsu Cancer Institute & Hospital

Completed

Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Radiation-Induced Temporal Lobe Injury

China
Jiangsu Cancer Institute & Hospital

Terminated

NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation

Nasopharyngeal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Completed

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Recruiting

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Non-small Cell Lung Cancer

China
Jiangsu Cancer Institute & Hospital

Recruiting

A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer

Colorectal Cancer

China
Jiangsu Cancer Institute & Hospital

Recruiting

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Jiangsu Cancer Institute & Hospital

Completed

An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Jiangsu Cancer Institute & Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma
Xiaoxiang Chen

Not yet recruiting

Variance of HRD From Paired Ovarian Cancer (HOPEII)

Ovarian Cancer | HRD | Platinum-sensitive Ovarian Cancer

China
Xiaoxiang Chen

Recruiting

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer (ROMP)

Ovarian Cancer | PARP Inhibitor | Clinical Marker

China
Xiaoxiang Chen

Recruiting

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ANLOLA)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Adnexal Diseases | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Angiogenesis | Genital Diseases, Female | Antineoplastic Agents | BRCA1... and other conditions

China
Xiaoxiang Chen

Not yet recruiting

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients (HOPEI)

Ovarian Cancer | HRD | PARP Inhibitor

China
Xiaoxiang Chen

Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Adnexal Diseases | Gonadal Disorders | Endocrine Gland Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms and other conditions

China
He Xia

Unknown

Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma (NPC-RCT-WCRT)

Nasopharyngeal Carcinoma
Sinobioway Cell Therapy Co., Ltd.
Jiangsu Cancer Institute & Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma (EECPL)

Lymphoma

China
Jinling Hospital, China
Jiangsu Cancer Institute & Hospital; Peking Union Medical College; Subei People...

Completed

GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer

Malnutrition | Muscle Loss | Cancer of Stomach | Cancer of Esophagus
FENG Ji-feng
Chinese Anti-Cancer Association

Unknown

R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL

Diffuse Large B-cell Lymphoma

China
Liangjun Zhu M.M.
Zhangjiagang First People's Hospital

Recruiting

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Metastatic or Recurrent Gastric Adenocarcinoma

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Peking University Cancer Hospital & Institute
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Completed

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Ovarian Cancer | Triple Negative Breast Cancer

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Non-Small-Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Recruiting

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Relapsed or Refractory Mature Lymphoid Neoplasms

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Peking University Cancer Hospital & Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

China
Jiangxi Provincial Cancer Hospital

Recruiting

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangxi Provincial Cancer Hospital

Recruiting

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Nasopharyngeal Carcinoma | Tumor Microenvironment | Pathologic Complete Response

China
Jiangxi Provincial Cancer Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor (ST-CR01)

Metastatic Cancer

China
Jiangxi Provincial Cancer Hospital

Recruiting

Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangxi Provincial Cancer Hospital

Not yet recruiting

Thalidomide With or Without Probiotics in Radioactive Oral Mucositis

Quality of Life | Oral Mucositis

China
Jiangxi Provincial Cancer Hospital

Completed

Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms
Jiangxi Provincial Cancer Hospital

Unknown

Effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Oral Mucositis in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy.

Quality of Life | Oral Mucositis

China
Cancer Institute and Hospital, Chinese Academy...
Henan Cancer Hospital; Beijing Hospital; Jiangsu Cancer Institute & Hospital; Liaoning...

Completed

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Jiangxi Provincial Cancer Hospital

Recruiting

The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Hypothyroidism | Nasopharyngeal Cancer

China
Jiangxi Provincial Cancer Hospital

Recruiting

Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis

Quality of Life | Nasopharyngeal Carcinoma | Bacterial Colonization | Radiation-induced Oral Mucositis

China
Jiangxi Provincial Cancer Hospital

Recruiting

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

HER2-positive Metastatic Breast Cancer

China

Clinical Trials Sponsored by Jiangsu Cancer Institute & Hospital

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations